

Maldives

Tuberculosis profile

Population 2017

<1 million

Estimates of TB burden*, 2017	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.016 (0.015–0.018)	3.7 (3.4–4.1)
Mortality (HIV+TB only)	0 (0–0)	0 (0–0)
Incidence (includes HIV+TB)	0.17 (0.13–0.22)	39 (30–49)
Incidence (HIV+TB only)	0 (0–0)	0 (0–0)
Incidence (MDR/RR-TB)**	<0.01 (0–0.012)	0.91 (0.08–2.7)

Estimated TB incidence by age and sex (thousands)*, 2017

	0-14 years	> 14 years	Total
Females	<0.01 (<0.01–<0.01)	0.055 (0.047–0.062)	0.063 (0.053–0.072)
Males	<0.01 (<0.01–<0.01)	0.099 (0.08–0.12)	0.11 (0.086–0.13)
Total	0.017 (0.015–0.018)	0.15 (0.12–0.19)	0.17 (0.13–0.22)

TB case notifications, 2017

Total cases notified	136
Total new and relapse	136
- % tested with rapid diagnostics at time of diagnosis	45%
- % with known HIV status	100%
- % pulmonary	72%
- % bacteriologically confirmed among pulmonary	100%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2017	80% (63–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2017	0.1 (0.07–0.12)

TB/HIV care in new and relapse TB patients, 2017

	Number	(%)
Patients with known HIV-status who are HIV-positive	0	0%
- on antiretroviral therapy	0	

Drug-resistant TB care, 2017	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			2 (0–5)
Estimated % of TB cases with MDR/RR-TB	1.7% (0.04–9.1)	18% (11–26)	
% notified tested for rifampicin resistance	56%		75
MDR/RR-TB cases tested for resistance to second-line drugs			1
Laboratory-confirmed cases		MDR/RR-TB: 1, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 1, XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2016	83%	168
Previously treated cases, excluding relapse, registered in 2016		
HIV-positive TB cases registered in 2016	100%	1
MDR/RR-TB cases started on second-line treatment in 2015	0%	1
XDR-TB cases started on second-line treatment in 2015		0

TB preventive treatment, 2017

% of HIV-positive people (newly enrolled in care) on preventive treatment	0%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	0% (0–0)

TB financing, 2018

National TB budget (US\$ millions)	<1
------------------------------------	----


* Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history


**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2017



■ Females ■ Males □ Incidence

Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB